MORPHINE SULPHATE 30MG/ML SOLUTION FOR INJECTION

Active substance: MORPHINE SULPHATE

View full screen / Print PDF » Download PDF ⇩

Transcript
INFORMATION FOR HEALTHCARE PROFESSIONALS
1 NAME OF THE MEDICINAL PRODUCT
Morphine Sulphate 10mg/ml Solution for Injection
Morphine Sulphate 15mg/ml Solution for Injection
Morphine Sulphate 30mg/ml Solution for Injection
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
The symptomatic relief of severe pain; relief of dyspnoea of left ventricular
failure and pulmonary oedema; pre-operative use.
4.2 Posology and method of administration
Morphine Sulphate may be given by the subcutaneous, intramuscular or
intravenous route. The subcutaneous route is not suitable for oedematous
patients. The dosage should be based on the severity of the pain and the
response and tolerance of the individual patient. The epidural or intrathecal
routes must not be used as the product contains a preservative.
Adults:
Subcutaneous or intramuscular injection:
10mg every four hours if necessary (the dose may vary from 5-20mg
depending on the individual patient).
Slow intravenous injection (2mg/minute):
Quarter to half of corresponding intramuscular dose not more than four
hourly.
Elderly and debilitated patients: The dose should be reduced
because of the depressant effect on respiration. Caution is required.
Children: Use in children is not recommended.
Hepatic impairment:
A reduction in dosage should be considered in hepatic impairment.
Renal impairment:
The dosage should be reduced in moderate to severe renal impairment.
For concomitant illnesses/conditions where dose reduction may be
appropriate see 4.4 Special warnings and precautions for use.
4.3 Contraindications
Acute respiratory depression, known morphine sensitivity, biliary colic
(see also biliary tract disorders 4.4 Special Warnings and Precautions),
acute alcoholism. Conditions in which intracranial pressure is raised,
comatose patients, head injuries, as there is an increased risk of
respiratory depression that may lead to elevation of CSF pressure.
The sedation and pupillary changes produced may interfere with accurate
monitoring of the patient. Morphine is also contraindicated where there is
a risk of paralytic ileus, or in acute diarrhoeal conditions associated with
antibiotic-induced pseudomembranous colitis or diarrhoea caused by
poisoning (until the toxic material has been eliminated).
Phaeochromocytoma (due to the risk of pressor response to histamine
release).
4.4 Special warnings and precautions for use
Morphine should be given in reduced doses or with caution to patients
with asthma or decreased respiratory reserve (including cor pulmonale,
kyphoscoliosis, emphysema, severe obesity). Avoid use during an acute
asthma attack (see 4.3 Contraindications). Opioid analgesics in general
should be given with caution or in reduced doses to patients with
hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy, urethral
stricture, hypotension, shock, inflammatory or obstructive bowel disorders,
or convulsive disorders.
Opioids such as morphine should either be avoided in patients with biliary
disorders or they should be given with an antispasmodic.
Morphine can cause an increase in intrabiliary pressure as a result
of effects on the sphincter of Oddi. Therefore in patients with biliary
tract disorders morphine may exacerbate pain (use in biliary colic
is a contraindication, see 4.3). In patients given morphine after
cholecystectomy, biliary pain has been induced.
Caution is advised when giving morphine to patients with impaired liver
function due to its hepatic metabolism (see 4.2 Posology).
Severe and prolonged respiratory depression has occurred in patients
with renal impairment who have been given morphine (see 4.2 Posology).
Dependence can develop rapidly with regular abuse of opioids but is
less of a problem with therapeutic use. Abrupt withdrawal from persons
physically dependent on them precipitates a withdrawal syndrome, the
severity of which depends on the individual, the drug used, the size and
frequency of the dose and the duration of drug use.
Great caution should be exercised in patients with a known tendency or
history of drug abuse.
Dosage should be reduced in elderly and debilitated patients
(see 4.2 Posology).

106963/1
Palliative care - in the control of pain in terminal illness, these conditions
should not necessarily be a deterrent to use.
4.5 Interactions with other medicinal products and other forms of
interaction
Alcohol: enhanced sedative and hypotensive effects.
Anti-arrhythmics: There may be delayed absorption of mexiletine.
Antibacterials: The opioid analgesic papaveretum has been shown to
reduce plasma ciprofloxacin concentration.
The manufacturer of ciprofloxacin advises that premedication with opioid
analgesics be avoided.
Antidepressants, anxiolytics, hypnotics: Severe CNS excitation or
depression (hypertension or hypotension) has been reported with the
concurrent use of pethidine and monoamine oxidase inhibitors (MAOIs)
including selegiline, moclobemide and linezolid. As it is possible that
a similar interaction may occur with other opioid analgesics, morphine
should be used with caution and consideration given to a reduction in
dosage in patients receiving MAOIs.
The sedative effects of morphine (opioid analgesics) are enhanced when
used with depressants of the central nervous system such as hypnotics,
anxiolytics, tricyclic antidepressants and sedating antihistamines.
Antipsychotics: possible enhanced sedative and hypotensive effect.
Antidiarrhoeal and antiperistaltic agents (such as loperamide and
kaolin): concurrent use may increase the risk of severe constipation.
Antimuscarinics: agents such as atropine antagonise morphineinduced respiratory depression and can partially reverse biliary spasm
but are additive to the gastrointestinal and urinary tract effects.
Consequently, severe constipation and urinary retention may occur during
intensive antimuscarinic-analgesic therapy.
Metoclopramide and domperidone: There may be antagonism of the
gastrointestinal effects of metoclopramide and domperidone.
4.6 Pregnancy and lactation
Morphine sulphate should only be used when benefit is known to
outweigh risk. As with all drugs it is not advisable to administer morphine
during pregnancy.
Morphine crosses the placental barrier. Administration during labour may
cause respiratory depression in the new born infant and gastric stasis
during labour, increasing the risk of inhalation pneumonia. Therefore, it is
not advisable to administer morphine during labour.
Babies born to opioid-dependent mothers may suffer withdrawal
symptoms including CNS hyperirritability, gastrointestinal dysfunction,
respiratory distress and vague autonomic symptoms including yawning,
sneezing, mottling and fever.
While morphine can suppress lactation, the quantity from therapeutic
doses that may reach the neonate via breast milk is probably insufficient
to cause major problems of dependence or adverse effects.
4.7 Effects on ability to drive and use machines
Morphine causes drowsiness so patients should avoid driving or operating
machinery.
This medicine can impair cognitive function and can affect a patient’s
ability to drive safely. This class of medicine is in the list of drugs
included in regulations under 5a of the Road of Traffic Act 1988. When
prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine.
•  owever, you would not be committing an offence (called ‘statutory
H
defence’) if:

treat a medical or
˚ tyhe medicine hasitbeen prescribed toinstructions given dental problem and
 ou
by
˚ and have taken according to the the medicine and the prescriber
in the information provided with
it was not affecting your ability to drive safely.
˚
4.8 Undesirable effects
The most serious hazard of therapy is respiratory depression (see also
4.9 Overdose). Morphine Injection contains sodium metabisulphite, which
may rarely cause severe hypersensitivity reactions and bronchospasm.
The commonest side-effects of morphine are nausea, vomiting,
constipation, drowsiness and dizziness. Tolerance generally develops with
long term use, but not to constipation.
Other side effects include the following:
Anaphylaxis: Anaphylactic reactions following intravenous injection have
been reported rarely.
Cardiovascular: facial flushing bradycardia, palpitations, tachycardia,
orthostatic hypotension.

521991
Artwork No.

English
Language

09/06/2014

UK
Market

Date

IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING
FULL APPROVAL OF DESIGN AND TEXT.

6.5pt (Main Body Text 9pt)
Min. Point Size

4

150 x 460mm
Size

Proof No.

W-LFT001

Profile

gill.kennedy

106963-1
Item Code

Proof By

Morphine sulphate amp common leaflet
Description

Pharma
Code

213

Keyline (non-printing)

Process Black

Colours Used

Text Free Area (non-printing)

Warning! We cannot accept responsibility for any errors
in this proof after approval. Whilst we take extreme care
at all times to ensure accuracy to our clientʼs brief,
the final responsibility must be taken by our client.

W
2.  HAT YOU NEED TO KNOW BEFORE YOU
ARE GIVEN MORPHINE INJECTION
Morphine Injection should not be given if you:
•  re allergic to morphine sulphate or any of the
a
other ingredients of this medicine (listed in
section 6)
•  ave been told you have a tumour of the
h
adrenal gland near your kidney called
phaeochromocytoma
• have severe problems with breathing
•  ave increased pressure on the brain, have just
h
had a head injury or if you are unconscious
• are suffering from acute alcoholism
• are at risk from a blocked intestine
 (paralytic ileus)
•  ave severe stomach cramps caused by a
h
condition known as biliary colic
• are suffering from severe diarrhoea
Warnings and precautions
Talk to your doctor before Morphine Injection
is given to you if you:
• are using drugs or have used drugs in the past
•  uffer from asthma (your doctor may decide to
s
administer Morphine Injection if your asthma is
controlled. However, you should not be given
this medicine if you are having an acute asthma
attack)
•  uffer from bronchitis (an inflammation of the
s
lining of the tubes in the lungs, resulting in
coughing spells accompanied by thick phlegm
and breathlessness) or emphysema (a lung
condition which leaves you struggling for breath)
• suffer from cor-pulmonale (a type of heart failure)
• are severely obese
• have a severely deformed spine
•  re suffering from mental illness brought on by an
a
infection
• have liver problems
• have kidney problems
• have problems with your bile duct
•  uffer from an enlarged prostate gland (in men)
s
or have difficulty passing urine
• have an under-active thyroid or adrenal gland

Wockhardt UK Limited

1.  HAT MORPHINE INJECTION IS AND
W
WHAT IT IS USED FOR
Morphine is one of a group of medicines called
opioid analgesics, which are used to relieve
moderate to severe pain. Morphine is used for
the relief of severe pain. It is also used to treat
breathlessness caused by fluid in the lungs and as a
pre-medication before operations.

Customer

What is in this leaflet:
1.  hat Morphine Injection is and what it is used for
W
2.  hat you need to know before you are given
W
Morphine Injection
3. How Morphine Injection should be given
4. Possible side effects
5. How to store Morphine Injection
6. Contents of the pack and other information

• have low blood pressure
• are in a state of severe shock
• are very run down
•  ave bowel disease, such as Crohn’s disease or
h
ulcerative colitis
•  uffer from blockages of the bowel
s
• suffer from convulsions (fits)
• are elderly
• are feeling weak and feeble
If any of the above applies to you, speak to your
doctor or nurse before Morphine Injection is given
to you.
Children
This medicine is not recommended for use in
children.
Other medicines and Morphine Injection
Tell your doctor if you are taking, have recently
taken or might take any other medicines. In
particular, tell your doctor if you are taking any of
the following:
m
•  onoamine oxidase inhibitors (MAOIs) such as
moclobemide or phenelzine used in the treatment
of depression.
t
•  ricyclic antidepressants, which are used in the
treatment of depression
•  ranquillising drugs or sleeping tablets such as
t
diazepam, nitrazepam and temazepam.
•  edicines used to treat mental illnesses,
m
including schizophrenia (e.g. chlorpromazine,
haloperidol).
•  edicines used for diarrhoea (e.g. loperamide,
m
kaolin).
•  edicines which are used as premedication
m
before operations and after heart attacks such as
atropine.
•  edicines used to treat nausea and vomiting,
m
such as metoclopramide or domperidone
• mexiletine, used to control heart rhythm.
•  ome antihistamines, used to treat allergies,
s
hayfever and asthma.
•  ertain antibiotics, used to treat infections
c
(e.g. ciprofloxacin and linezolid).
s
•  elegiline, used in the treatment of Parkinson’s
disease.
• pethidine, used to treat pain.
Morphine Injection with food, drink and
alcohol
You should not drink alcohol whilst being given
Morphine Injection, as it will increase its effects.
Pregnancy and breast-feeding
You should not be given morphine if you are
pregnant or think you might be pregnant unless you
have discussed this with your doctor first. If you
are given morphine during pregnancy and become
dependent on it, there is a risk that the new-born
baby may also be dependent and suffer from
withdrawal symptoms following delivery. If you are
given morphine during labour there is a risk that you
could be sick and have breathing difficulties, or the
baby could have difficulty starting breathing.
If you are breast-feeding, ask your doctor for advice
before taking this medicine.
Driving and using machines
If the injection makes you feel drowsy, do not drive
or operate machinery.
This medicine can affect your ability to drive.
Do not drive whilst taking this medicine until you
know how this medicine affects you.
It may be an offence to drive if your ability to drive
safely is affected.
There is further information for patients who are
intending to drive in Great Britain - go to
http://www.gov.uk/drug-driving-law
Morphine Injection contains sodium
metabisulphite
Sodium metabisulphite may rarely cause severe
hypersensitivity reactions and wheezing.

Measure bar should be 150mm at 100% scale

PACKAGE LEAFLET: INFORMATION FOR
THE USER
Morphine Sulphate 10mg/ml, 15mg/ml and
30mg/ml Solution for Injection
Read all of this leaflet
carefully before you
start using this medicine
because it contains
important information for
you.
-  eep this leaflet. You may
K
need to read it again.
- f you have further
I
questions, please ask
your doctor, pharmacist or
nurse.
- f you get any side effects, talk to your doctor,
I
pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.

Central Nervous System: myoclonus, mental clouding, confusion
(with large doses), hallucinations, headache, vertigo, mood changes
including dysphoria and euphoria.
Gastrointestinal: dry mouth, biliary spasm.
Disorders of the eye: blurred or double vision or other changes in
vision, miosis.
Sexual dysfunction: long term use may lead to a reversible decrease in
libido or potency.
Skin: pruritus, urticaria, rash, sweating. Contact dermatitis has been
reported and pain and irritation may occur on injection.
Urinary: difficulty with micturition, ureteric spasm, urinary retention,
antidiuretic effect. Tolerance develops to the effects of opioids on the
bladder.
The euphoric activity of morphine has led to its abuse and physical and
psychological dependence may occur (see also 4.4 Special warnings and
precautions for use).
4.9 Overdose
Toxic doses vary considerably with the individual, and regular users may
tolerate large doses.
The triad of respiratory depression, coma and constricted pupils is
considered indicative of opioid overdosage with dilatation of the pupils
occurring as hypoxia develops. Death may occur from respiratory failure
Other opioid overdose symptoms include hypothermia, confusion, severe
dizziness, severe drowsiness, hypotension, bradycardia, circulatory
failure, pulmonary oedema, severe nervousness or restlessness,
hallucinations, convulsions (especially in infants and children).
Rhabdomyolysis, progressing to renal failure, has been reported in
overdosage.
Treatment: The medical management of overdose involves prompt
administration of the specific opioid antagonist naloxone if coma or
bradypnoea are present using one of the recommended dosage regimens.
Both respiratory and cardiovascular support should be given where
necessary.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Morphine is obtained from opium, which acts mainly on the CNS and
smooth muscle.
Morphine is a potent analgesic with competitive agonist actions at the
μ-receptor, which is thought to mediate many of its other actions of
respiratory depression, euphoria, inhibition of gut motility and physical
dependence. It is possible that analgesia, euphoria and dependence
may be due to the effects of morphine on a μ-1 receptor subtype, while
respiratory depression and inhibition of gut motility may be due to actions
on a μ-2 receptor subtype. Morphine is also a competitive agonist at
the κ-receptor that mediates spinal analgesia, miosis and sedation.
Morphine has no significant actions at the other two major opioid
receptors, the δ- and the σ-receptors.
Morphine directly suppresses cough by an effect on the cough centre in
the medulla. Morphine also produces nausea and vomiting by directly
stimulating the chemoreceptor trigger zone in the area postrema of the
medulla. Morphine provokes the release of histamine.
5.2 Pharmacokinetic particulars
Absorption:
 ariably absorbed after oral administration; rapidly
V
absorbed after subcutaneous or intramuscular
administration.
Blood concentration:  fter an oral dose of 10mg as the sulphate, peak
A
serum concentrations of free morphine of about
10ng/ml are attained in 15 to 60 minutes.


 fter an intramuscular dose of 10mg, peak serum
A
concentrations of 70 to 80ng/ml are attained in 10
to 20 minutes.
  fter an intravenous dose of 10mg, serum
A


concentrations of about 60ng/ml are obtained in
15 minutes falling to 30ng/ml after 30 minutes and
to 10ng/ml after three hours.

S
 ubcutaneous doses give similar concentrations
to intramuscular doses at 15 minutes but remain
slightly higher during the following three hours;
serum concentrations measured soon after
administration correlate closely with the ages of the
subjects studied and are increased in the elderly.
S
Half-life
  erum half-life in the period ten minutes to six
hours following intravenous administration-two to
three hours; serum half-life in the period six hours
onwards-10 to 44 hours.

Product Name
Morphine Sulphate 10mg/ml
Solution for Injection
Morphine Sulphate 15mg/ml
Solution for Injection
Morphine Sulphate 30mg/ml
Solution for Injection

Reference Number
29831/0146
29831/0145
29831/0147

This is a service provided by the Royal National
Institute of Blind People.
This leaflet was last revised in 06/2014.
106963/1

Distribution:  Widely distributed throughout the body, mainly
in the kidneys, liver, lungs and spleen; lower
concentrations appear in the brain and muscles.
 Morphine crosses the placenta and traces are

secreted in sweat and milk.
 Protein binding-about 35% bound to albumin and

to immunoglobulins at concentrations within the
therapeutic range.
Metabolic reactions:  Mainly glucuronic acid conjugation to

form morphine-3 and 6-glucuronides.
N-demethylation, O-methylation and N-oxide
glucuronide formation occurs in the intestinal
mucosa and liver; N-demethylation occurs
to a greater extent after oral than parental
administration; the O-methylation pathway to form
codeine has been challenged and codeine and
norcodeine metabolites in urine may be formed
from codeine impurities in the morphine sample
studied.
Excretion:
  fter an oral dose, about 60% is excreted in the
A
urine in 24 hours, with about 3% excreted as free
morphine in 48 hours.


  fter a parental dose, about 90% is excreted in
A
24 hours, with about 10% as free morphine, 65 to
70% as conjugated morphine, 1% as normorphine
and 3% as normorphine glucuronide.


  fter administration of large doses to addicts
A
about 0.1% of a dose is excreted as norcodeine.


  rinary excretion of morphine appears to be pH
U
dependent to some extent; as the urine becomes
more acidic more free morphine is excreted and
as the urine becomes more alkaline more of the
glucuronide conjugate is excreted.


Up to 10% of a dose may be excreted in the bile.
5.3 Preclinical safety data
There are no pre-clinical data of relevance to the prescriber, which are
additional to those included in other sections.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Water for injections
Sodium metabisulphite (E223)
Sodium hydroxide
Hydrochloric acid
6.2 Incompatibilities
Morphine salts are sensitive to changes in pH and morphine is liable to
be precipitated out of solution in an alkaline environment. Compounds
incompatible with morphine salts include aminophylline and sodium
salts of barbiturates and phenytoin. Other incompatibilities (sometimes
attributed to particular formulations) have included aciclovir sodium,
doxorubicin, fluorouracil, furosemide, heparin sodium, pethidine
hydrochloride, promethazine hydrochloride and tetracyclines. Specialised
references should be consulted for specific compatibility information.
6.3 Shelf life
36 months
6.4 Special precautions for storage
Do not store above 25°C. Keep container in the outer carton.
6.5 Nature and contents of container
10mg
5 × 1ml Type I glass ampoules
10 × 1ml Type I glass ampoules
15mg
5 × 1ml glass ampoules
10 × 1ml glass ampoules
30mg
5 × 1ml Type I glass ampoules
10 × 1ml Type I glass ampoules
5 × 2ml Type I glass ampoules
6.6 Special precautions for disposal
None

106963/1

213
Pharma
Code

Artwork No.

521991

09/06/2014
Date

IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING
FULL APPROVAL OF DESIGN AND TEXT.

English
Language

4

UK
Market

Proof No.

6.5pt (Main Body Text 9pt)
Min. Point Size

gill.kennedy

150 x 460mm
Size

Proof By

W-LFT001

Profile

The active substance is morphine sulphate. The
injection is available in three strengths, 10mg/ml
(10mg of active ingredient in 1ml of solution),
15mg/ml (15mg of active ingredient in 1ml of
solution) and 30mg/ml (30mg of active ingredient in
1ml of solution).
Other ingredients are water for injections, sodium
metabisulphite (E223), hydrochloric acid and
sodium hydroxide.
What Morphine Injection looks like and
contents of the pack
Morphine Injection is a colourless or almost
colourless solution, practically free from particles.
Morphine Sulphate 10mg/ml Solution for Injection
is available in cartons containing 5 × 1ml glass
ampoules and 10 × 1ml glass ampoules.
Morphine Sulphate 15mg/ml Solution for Injection
is available in cartons containing 5 × 1ml glass
ampoules and 10 × 1ml glass ampoules.
Morphine Sulphate 30mg/ml Solution for Injection
is available in cartons containing 5 × 1ml glass
ampoules and 10 × 1ml glass ampoules. It is also
available in cartons containing 5 x 2ml ampoules.
Not all strengths and pack sizes may be marketed.
Marketing Authorisation Holder: Wockhardt UK
Ltd, Ash Road North, Wrexham, LL13 9UF, UK
Manufacturer: CP Pharmaceuticals Ltd, Ash Road
North, Wrexham, LL13 9UF, UK.
Other sources of information:
To listen to or request a copy of this leaflet in
Braille, large print or audio please call, free of
charge:
0800 198 5000 (UK Only)
Please be ready to give the following information:

Text Free Area (non-printing)

106963-1
Item Code

What Morphine Injection contains

Keyline (non-printing)

Morphine sulphate amp common leaflet
Description

6.  ONTENTS OF THE PACK AND OTHER
C
INFORMATION

Process Black

Colours Used
Wockhardt UK Limited

5.  OW TO STORE MORPHINE INJECTION
H

Keep out of the sight and reach of children.
Store below 25°C. Keep the ampoule in its outer
carton, in order to protect it from light.
Do not use this medicine if you notice signs of
discolouration.
Do not use this medicine after the expiry date which
is stated on the carton. The expiry date refers to the
last day of that month.
Do not throw away any medicines via wastewater
or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These
medicines will help protect the environment.

Warning! We cannot accept responsibility for any errors
in this proof after approval. Whilst we take extreme care
at all times to ensure accuracy to our clientʼs brief,
the final responsibility must be taken by our client.

4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side
effects, although not everybody gets them.
Tell your doctor or nurse immediately if you
experience the following serious side effect:
•  severe allergic reaction, such as breathing
A
difficulties, shock or low blood pressure. If you
suffer such a reaction, you should not be given
any more morphine. Your doctor will decide on
the appropriate treatment for allergic reactions.
Difficulty in breathing and physical and
psychological dependence are possible serious
side effects. It is possible that you could become
dependent on morphine.
Side effects that are common include:
• drowsiness
• feeling sick or being sick
• constipation
• dizziness.
Apart from constipation, these side effects tend to
disappear with time.
Side effects that are less common include:
• sweating
• feeling faint on standing up
• small pupils (in the eye)
• blurred vision
• double vision or other changes in vision
• mental clouding or confusion
•  ood changes, feeling extremely happy for no
m
particular reason, or a feeling of emotional and
mental unease (dysphoria)
• imagining things (hallucinations)
• headache
• vertigo
• facial flushing
• dry mouth
• difficulty or pain in passing urine
• passing less urine than usual
•  iliary spasm (causing pain in the right side of
b
your abdomen, particularly after eating a meal,
which may spread towards your right shoulder)
• palpitations (being aware of your heart beat)
• slower or faster pulse
• skin rash
• wheals (lumpy, red rash) or itching
• red, itchy, scaly skin at the injection site

Customer

The usual adult dose for relief of pain by
subcutaneous injection (an injection underneath
the skin) or intramuscular injection (an injection into
a muscle) is 10mg every four hours, if necessary.
However, this can vary between 5mg and 20mg
depending on your size and response to the drug.
For severe pain your doctor may give you a slow
intravenous injection (an injection given slowly into
a vein). The usual dose is quarter to half of the
intramuscular dose.
• f you are elderly, severely run down including
I
feeling weak and feeble, or have liver and kidney
problems the dose will be lower. You may also
be given a reduced dose if you suffer from any of
the conditions listed in section 2 entitled “Talk to
your doctor before Morphine Injection is given to
you if you.”
•  our doctor will decide the dose that is best for
Y
you. If you do not understand what you are being
given, or are in any doubt, ask your doctor or
nurse.
If you miss a dose of Morphine Injection
If you think that an injection has been missed,
speak to your doctor or nurse.
If treatment with Morphine Injection is
stopped
You should always check with your doctor before
the treatment is stopped. It is possible that you
could become dependent on morphine and have
withdrawal symptoms if it is stopped suddenly. This
is more likely if you have a tendency for drug abuse
or if you become dependent on Morphine Injection.
If you have any further questions on the use of this
medicine, ask your doctor or nurse.

• pain and irritation at the injection site
•  educed sexual drive or impotence after long term
r
use
•  uscle twitching.
m
Reporting of side effects
If you get any side effects,
talk to your doctor, pharmacist
or nurse. This includes any
possible side effects not listed
in this leaflet. You can also
report side effects directly via
the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard
By reporting side effects
you can help provide more
information on the safety of this medicine.
Measure bar should be 150mm at 100% scale

3.  OW MORPHINE INJECTION SHOULD BE
H
GIVEN

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web2)